BCLIOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
BRAINSTORM CELL THERAPEUTICS INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.77−0.01 (-1.17%)
Close on Oct 19, 2026
- Market cap
- $8.50M
- P/E (TTM)
- –
- Dividend yield
- –
Brainstorm Cell Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Brainstorm Cell Therapeutics | Industry median |
|---|---|---|
| Market Cap | $8.50M | $166.30M |
| Enterprise Value | $9.74M | $88.19M |
Income (trailing twelve months)
| Measure | Brainstorm Cell Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$9.95M | -$21.40M |
| Net Income | -$10.52M | -$22.46M |
| EBITDA | -$9.95M | -$16.91M |
| EPS (Diluted) | -$0.95 | -$0.83 |
Returns
| Measure | Brainstorm Cell Therapeutics | Industry median |
|---|---|---|
| Return on Assets (ROA) | -627.4% | -40.9% |
Balance sheet
| Measure | Brainstorm Cell Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $22.00K | $61.43M |
| Total Debt | $1.26M | $118.52M |
| Net Cash (Debt) | -$1.24M | $15.35M |
| Net Cash Per Share | -$0.11 | $0.66 |
| Equity (Book Value) | -$11.60M | $49.09M |
| Book Value Per Share | -$1.05 | $1.37 |
| Tangible Book Value | -$11.60M | $23.52M |
| Working Capital | -$12.07M | $76.81M |
Financial position
| Measure | Brainstorm Cell Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 0.03 | 3.34 |
| Quick Ratio | 0.00 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Brainstorm Cell Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$4.06M | -$12.35M |
Efficiency
| Measure | Brainstorm Cell Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$526.10K | -$703.34K |
| Employee Count | 20 | 74 |
Dividends and yields
| Measure | Brainstorm Cell Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -123.8% | -23.3% |
Shares
| Measure | Brainstorm Cell Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 11,034,800 | 58,127,000 |
| Shares Change (YoY) | 69.9% | 10.9% |
| Shares Change (QoQ) | 0.00% | 0.54% |
| Float | 7,771,840 | 49,136,700 |
| Shares Held by Insiders | 29.6% | 11.6% |
Scores
| Measure | Brainstorm Cell Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -491.23 | -0.22 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Brainstorm Cell Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.